Dianthus Therapeutics Announces $230 Million Private Placement
January 22, 2024 07:30 ET
|
Dianthus Therapeutics, Inc.
NEW YORK and WALTHAM, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus” or the “Company”) (NASDAQ: DNTH), a clinical-stage biotechnology company dedicated to advancing...
Dianthus Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024 08:30 ET
|
Dianthus Therapeutics, Inc.
NEW YORK and WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...
Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2023 16:09 ET
|
Dianthus Therapeutics, Inc.
NEW YORK and WALTHAM, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody...
Dianthus Therapeutics Enhances Leadership Team with Appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer
November 29, 2023 16:05 ET
|
Dianthus Therapeutics, Inc.
Dr. Stavenhagen brings over 20 years of experience in leading drug discovery initiatives, with a focus on monoclonal antibodies targeting neuro diseases Jennifer Davis Ruff also named Vice President,...
Dianthus Therapeutics Highlights Recent Business Achievements and Third Quarter 2023 Financial Results
November 09, 2023 16:05 ET
|
Dianthus Therapeutics, Inc.
Began trading on Nasdaq under the ticker symbol DNTH following the successful completion of our merger with Magenta Therapeutics Completed concurrent $72 million financing with a syndicate of leading...
Dianthus Therapeutics to Participate in Upcoming Investor Healthcare Conferences in November
November 01, 2023 16:32 ET
|
Dianthus Therapeutics, Inc.
NEW YORK and WALTHAM, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement...
Dianthus Therapeutics Announces Positive Top-line Phase 1 Data and Debuts Trading on Nasdaq as DNTH
September 12, 2023 07:30 ET
|
Dianthus Therapeutics, Inc.
Positive top-line Phase 1 data for lead clinical program DNTH103 confirm potent classical pathway inhibition, extended half-life, and a potentially differentiated safety profile Results support...
Magenta Therapeutics Announces Completion of Merger with Dianthus Therapeutics and Implementation of Reverse Stock Split
September 11, 2023 11:33 ET
|
Dianthus Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics, Inc. (Nasdaq: MGTA) (“Magenta”) today announced completion of the merger with Dianthus Therapeutics, Inc. (“Dianthus”)...